Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Cash & Current Investments: 2009-2025

Historic Cash & Current Investments for Corcept Therapeutics (CORT) over the last 13 years, with Sep 2025 value amounting to $421.7 million.

  • Corcept Therapeutics' Cash & Current Investments rose 10.87% to $421.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year decrease of 9.95%. This contributed to the annual value of $383.3 million for FY2024, which is 4.10% up from last year.
  • Corcept Therapeutics' Cash & Current Investments amounted to $421.7 million in Q3 2025, which was up 23.22% from $342.2 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Cash & Current Investments registered a high of $473.2 million during Q2 2024, and its lowest value of $223.5 million during Q4 2021.
  • Its 3-year average for Cash & Current Investments is $389.6 million, with a median of $380.3 million in 2024.
  • In the last 5 years, Corcept Therapeutics' Cash & Current Investments slumped by 49.28% in 2021 and then surged by 93.11% in 2022.
  • Over the past 5 years, Corcept Therapeutics' Cash & Current Investments (Quarterly) stood at $223.5 million in 2021, then surged by 93.11% to $431.7 million in 2022, then decreased by 14.70% to $368.2 million in 2023, then grew by 4.10% to $383.3 million in 2024, then grew by 10.87% to $421.7 million in 2025.
  • Its Cash & Current Investments stands at $421.7 million for Q3 2025, versus $342.2 million for Q2 2025 and $322.8 million for Q1 2025.